T

he death of a hemophilia patient due to a blood clot has forced Alnylam Pharmaceuticals (ALNY) to temporarily suspend studies of its gene-silencing drug fitusarin, the company said Thursday.

The new safety setback comes at a particularly bad time for the Cambridge, Mass.-based biotech company, developers of drugs based on a technology known as RNA interference, or RNAi. In the next days to weeks, Alnylam is expecting to receive and announce results from its first phase 3 clinical trial for a different drug called patisiran in a rare nerve condition.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.